Honeybee-associated lactic acid bacteria and their probiotic potential for human use

What We Know About the Actual Role of Traditional Probiotics in Health and Disease

The complex relationship between probiotics and human health goes beyond their traditional function in gut health, generating considerable interest for their broad potential in disease treatment. This review explores the various functions of probiotics, highlighting their impact on the immune system, their benefits for gut and oral health, their effects on metabolic and neurological disorders, and their emerging potential in cancer therapy. We give significant importance to studying the effects of probiotics on the gut-brain axis, revealing new and non-invasive therapeutic approaches for complex neurological disorders. In addition, we expand the discussion to encompass the impact of probiotics on the gut-liver and gut-lung axes, recognizing their systemic effects and potential in treating respiratory and hepatic conditions. The use of probiotic "cocktails" to improve cancer immunotherapy outcomes indicates a revolutionary approach to oncological treatments. The review explores the specific benefits associated with various strains and the genetic mechanisms that underlie them. This study sets the stage for precision medicine, where probiotic treatments can be tailored to meet the unique needs of each patient. Recent developments in delivery technologies, including microencapsulation and nanotechnology, hold great potential for enhancing the effectiveness and accuracy of probiotic applications in therapeutic settings. This study provides a strong basis for future scientific research and clinical use, promoting the incorporation of probiotics into treatment plans for a wide range of diseases. This expands our understanding of the potential benefits of probiotics in modern medicine.

Dataset of 16S ribosomal DNA sequence-based identification of bacteriocinogenic lactic acid bacteria isolated from fermented food samples

The dataset profiled in this research is built on sequencing of lactic acid bacteria 16S rDNA mined from Nono (N4 and N5), Kunu (K4 and K1) and Garri. The 16S rDNA sequences files are accessible under the data identification numbers: OK017047, OK017046, OK017044, OK017043, OK017045 at the GenBank database, NCBI. Taxonomic identification and phylogenetic tree analysis were done using the online BLAST (blastn) and MEGA11 software, respectively. The effect of the bacteriocin produced by these organisms on spoilage bacteria associated with salad was evaluated using an agar well diffusion assay. Limosilactobacillus pontis strain EOINONO, Limosilactobacillus pontis strain OGENONO, Limosilactobacillus pontis strain SEOGARI, Lactiplantibacillus plantarum strain MJIKUNU and Limosilactobacillus pontis strain EEIKUNU were the identified bacteriocinogenic organisms while Bacillus tequilensis strain SEOABACHA, Bacillus tequilensis strain EEIABACHA, Achromobacter xylosoxidans strain IMABACHA and Achromobacter insolitus strain MJIABACHA were the identified spoilage organisms.

Lysinibacillus capsici 38,328 isolated from agricultural soils as a promising probiotic candidate for intestinal health

There is an increasing interest in the use of spore-forming Bacillus spp. as probiotic ingredients on the market. However, probiotics Bacillus species are insufficient, and more safe Bacillus species were required. In the study, traditional fermented foods and soil samples were collected from more than ten provinces in China, and 506 Bacillus were selected from 109 samples. Using the optimized procedure, we screened nine strains, which successfully passed the acid, alkali, bile salt, and trypsin resistance test. Drug sensitivity test results showed that three Bacillus out of the nine isolates exhibited antibiotic sensitivity to more than 29 antibiotics. The three strains sensitive to antibiotics were identified by 16S ribosomal RNA, recA, and gyrB gene analysis, two isolates (38,327 and 38,328) belong to the species Lysinibacillus capsici and one isolate (37,326) belong to Bacillus halotolerans. Moreover, the three strains were confirmed safe through animal experiments. Finally, L. capsici 38,327 and 38,328 showed protections in the Salmonella typhimurium infection mouse model, which slowed down weight loss, reduced bacterial load, and improved antioxidant capacity. Altogether, our data demonstrated that selected L. capsici strains can be used as novel probiotics for intestinal health.